CRISPR Therapeutics AG (LTS:0VRQ) Notes Receivable: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0VRQ CRISPR Therapeutics AG LTS:0VRQ
37 GF Score
Price $52.63
! 3 Warning Signs
View Full Analysis

What is CRISPR Therapeutics AG Notes Receivable?

CRISPR Therapeutics AG LTS:0VRQ +0.71% 37 Notes Receivable is $0.00 Mil as of Jun. 2026. GuruFocus rates LTS:0VRQ with a GF Score™ of 37/100. The stock has 3 warning signs investors should review.

CRISPR Therapeutics AG's Notes Receivable for the quarter that ended in Jun. 2026 was $0.00 Mil.

CRISPR Therapeutics AG Notes Receivable Related Terms

CRISPR Therapeutics AG Notes Receivable Historical Data

* Premium members only.

The historical data trend for CRISPR Therapeutics AG's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CRISPR Therapeutics AG Notes Receivable Chart

CRISPR Therapeutics AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CRISPR Therapeutics AG Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LTS:0VRQ
37GF Score
CRISPR Therapeutics AG LTS:0VRQ
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CRISPR Therapeutics AG Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
CRISPR Therapeutics AG (LTS:0VRQ) has a Notes Receivable of $0.00 Mil as of Jun. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on CRISPR Therapeutics AG and its competitors.
Is CRISPR Therapeutics AG's Notes Receivable too high?
CRISPR Therapeutics AG's current Notes Receivable is $0.00 Mil. Overall, CRISPR Therapeutics AG has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does CRISPR Therapeutics AG's Notes Receivable compare to MANE and EWTX?
CRISPR Therapeutics AG's Notes Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on CRISPR Therapeutics AG and its competitors. CRISPR Therapeutics AG's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CRISPR Therapeutics AG stock overvalued right now?
CRISPR Therapeutics AG (LTS:0VRQ) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. CRISPR Therapeutics AG's overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For CRISPR Therapeutics AG (LTS:0VRQ), the current Notes Receivable is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CRISPR Therapeutics AG Business Description

Address Baarerstrasse 14, Zug, CHE, 6300
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
37GF Score

Get the complete analysis for LTS:0VRQ

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$52.63
Price